MedinCell SA (0ACH) Share Price & Analysis
0ACH Stock Chart & Stats
- Day’s Range
- EUR 28.42 - EUR 29.84
- 52-Week Range
- EUR 19.69 - EUR 35.84
- Previous Close
- EUR 28.72
- Volume
- N/A
- Average Volume (3M)
- 3,367
- Market Cap
- EUR 1.03B
- Enterprise Value
- EUR 731.65M
- Total Cash (Recent Filing)
- EUR 84.82M
- Total Debt (Recent Filing)
- EUR 57.41M
- Price to Earnings (P/E)
- ―
- Beta
- 0.86
- Next Earnings
- Dec 09, 2026 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Royalty Growth
The rising royalty share indicates a durable shift toward recurring, asset-light revenue rather than reliance on one-time milestones. Strong UZEDY sales growth and Teva’s potential $300M 2026 sales outlook could improve revenue quality and support future operating leverage.
Olanzapine Regulatory Progress
FDA acceptance and European filing materially advance a second potential royalty engine beyond UZEDY. If approval and launch remain on schedule, olanzapine could diversify revenue, broaden the commercial platform, and provide meaningful royalties from 2027.
Expanding Partnered Pipeline
A broad internal and partner-funded pipeline increases the number of opportunities that can validate BEPO and generate future milestones or royalties. Advancing the AbbVie collaboration toward clinical testing also supports platform credibility and longer-term portfolio depth.
Bears Say
Persistent Losses And Cash Burn
Sustained losses and renewed cash consumption show that commercial progress has not yet translated into self-funded operations. Continued investment may accelerate the pipeline, but it also increases reliance on liquidity, future monetization, or additional funding.
Revenue Volatility From Milestones
Dependence on milestone receipts makes reported revenue uneven and reduces visibility into underlying growth from period to period. Although recurring royalties are improving, absent deal payments can still materially affect results while the company scales its commercial base.
Partner And Regulatory Execution Risk
MedinCell’s development and commercialization model relies substantially on partners to execute sales, approvals, and clinical plans. Delays, conservative guidance, or changed regulatory pathways could postpone royalties and weaken the timing of expected pipeline value.
MedinCell SA News
0ACH FAQ
What was MedinCell SA’s price range in the past 12 months?
What is MedinCell SA’s market cap?
When is MedinCell SA’s upcoming earnings report date?
How were MedinCell SA’s earnings last quarter?
Is MedinCell SA overvalued?
Does MedinCell SA pay dividends?
What is MedinCell SA’s EPS estimate?
How many shares outstanding does MedinCell SA have?
What happened to MedinCell SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MedinCell SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christophe Douat
- Employees
- 141
- Website
- www.medincell.com
- Address
- 3 rue des Frères Lumière, Jacou, OC, 34830, FR
MedinCell SA (0ACH) Earnings & Revenues
0ACH Earnings Call
Earnings Call SentimentPositive
The call presents a largely positive strategic picture: strong commercial traction for UZEDY with high-teens to double-digit growth rates, clear regulatory progress for olanzapine LAI (NDA accepted) and an expanding partnered pipeline (15 formulation-stage programs, AbbVie program advancing toward clinic). Management is intentionally increasing investment to accelerate R&D and business development, which drove higher operating expenses and resulted in an operating and net loss this fiscal year, and there are near-term accounting and FX headwinds (non-cash EIB warrant revaluation, USD exposure) as well as some program-specific regulatory uncertainty. Overall, the company is in a transitional, investment-heavy phase with improving recurring royalty revenue that supports a positive outlook if commercial ramps and regulatory approvals proceed as expected.
View all GB:0ACH earnings summaries0ACH Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 4 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
